Novo Just Quietly Dropped a 25% Weight Loss Number

 Novo Just Quietly Dropped a 25% Weight Loss Number—And It's the Most Important Footnote in the Obesity Drug War

*

] | October 20, 2026 | 12-Minute Read**

---

## The Short Version (For the Busy American)

Novo Nordisk released a new analysis of its next-generation obesity drug CagriSema on Tuesday, and the headline number is the one every investor and every patient has been waiting for: **25% average weight loss in women** after 68 weeks .

But before you get too excited—or too worried if you're an Eli Lilly shareholder—you need to understand what that number actually is.

This wasn't the main trial result. It was a **post-study analysis** of women who stayed on the drug without interruptions. The "ideal scenario" caveat matters enormously. In the actual late-stage trial of more than 3,400 adults, CagriSema delivered **22.7% weight loss**—below the 25% Novo had originally targeted .

**The punchline:** Novo is trying to convince the market that its next-gen drug is a worthy successor to Wegovy. The 25% number is real, but it comes with asterisks. And with the FDA decision expected by late 2026 and a launch planned for early next year, every percentage point matters in a market where Eli Lilly's Zepbound already beat CagriSema in a head-to-head trial .

---

## What Novo Actually Announced

Let me break down the data, because the details are where the story lives.

### The 25% Number

In an analysis of roughly **2,300 women** with obesity or who were overweight, CagriSema caused **25% weight loss on average at 68 weeks**, compared with **3% with placebo**. The results were based on an "ideal scenario" in which all patients stayed on treatment without interruptions .

A second analysis of about **1,900 women** by menopausal status found weight loss of:

- **26.7%** in premenopausal women

- **24.8%** in perimenopausal women

- **23.1%** in postmenopausal women

All compared with roughly **2%** across menopause groups on placebo .

Novo also said CagriSema was linked to reductions in **abdominal fat**, based on waist circumference, across all groups .

### The Full Trial Reality

Here's the context that matters. The main trial included **more than 3,400 adults**—and about **67% were women**. The overall result was **22.7% weight loss** at 68 weeks, versus **2.3%** for placebo .

That's a stunning result in absolute terms. A drug that helps people lose nearly a quarter of their body weight is genuinely transformative. But it's **below the 25%** Novo had originally hoped for, and it's below what Eli Lilly's Zepbound achieved in a head-to-head trial.

### The Head-to-Head Wound

In the **REDEFINE 4** trial, CagriSema was tested directly against Eli Lilly's tirzepatide (sold as Zepbound for obesity and Mounjaro for diabetes). The result was painful for Novo:

- **CagriSema**: 23% weight loss at 84 weeks (among patients who adhered to treatment)

- **Zepbound**: 25.5% weight loss

CagriSema **failed to meet the primary endpoint** of demonstrating non-inferiority to Lilly's drug . The results sent Novo shares tumbling **15%** in premarket trading when they were announced in February .

---

## The Human Touch: What This Means for Real People

Let me put this in terms that actually connect to your life.

### If You're Struggling with Obesity

The drug works. A 22.7% average weight loss is life-changing for many people. It's the kind of result that can reverse type 2 diabetes, reduce blood pressure, improve sleep apnea, and restore mobility.

But the "25% in women" headline requires context. It's an **analysis of people who stayed on the drug**, not the real-world result for everyone who starts it. In clinical trials, a significant percentage of patients discontinue GLP-1 drugs due to side effects—mostly nausea, vomiting, and diarrhea. Those people don't get the full benefit.

The 25% number is real for the women who persisted. It's not the number every patient should expect.

### If You Own Novo Stock

You've been on a brutal ride. Novo shares have lost roughly **34%** over the past six months, while the broader industry has gained . The CagriSema disappointment, the head-to-head loss to Lilly, and a shareholder lawsuit alleging the company misled investors about trial design have all weighed on the stock .

The 25% women analysis is a small positive. It suggests CagriSema has meaningful efficacy in a key demographic. But it's not the clear win Novo needed. The market's reaction—Novo shares rose about **2%** in premarket trading, in line with the broader obesity drug sector—suggests investors see this as incremental, not transformative .

### The Lilly Comparison

Eli Lilly's Zepbound already has the efficacy crown. It beat CagriSema head-to-head. It's on the market. And Lilly has its own next-gen drugs in the pipeline, including an oral GLP-1 pill that could reshape the market again .

Novo's argument is that CagriSema will be the **first amylin-based product** to market, giving it a differentiated mechanism and a label that physicians will value . That may be true. But "first" isn't the same as "best," and in a market where patients and doctors are increasingly educated about weight loss percentages, efficacy matters.

---

## Frequently Asked Questions

### What exactly did Novo announce?

Novo released two post-study analyses of its late-stage CagriSema trial. The first showed **25% average weight loss in about 2,300 women** at 68 weeks, compared with 3% on placebo. The second showed weight loss across menopause statuses, ranging from 23.1% to 26.7%. Novo said further work is needed to confirm the hypotheses of these analyses .

### Why is the 25% number controversial?

Because it's based on an **"ideal scenario"** where all patients stayed on treatment without interruptions. The main trial result—which includes everyone who started the drug, including those who dropped out due to side effects—was **22.7%** weight loss. The 25% figure is a subset analysis, not the primary endpoint .

### How does CagriSema compare to Eli Lilly's Zepbound?

In a head-to-head trial called REDEFINE 4, **Zepbound delivered 25.5% weight loss** at 84 weeks among patients who adhered to treatment, compared with **23% for CagriSema**. CagriSema failed to meet the primary endpoint of non-inferiority. That result sent Novo shares down 15% when it was announced .

### What is CagriSema and how does it work?

CagriSema is a weekly injection that combines **semaglutide** (the active ingredient in Wegovy and Ozempic) with **cagrilintide**, a drug that mimics the hormone amylin. The combination targets two different pathways involved in appetite regulation and blood sugar control .

### When will CagriSema be available?

Novo has already submitted CagriSema to the FDA for weight management. A regulatory decision is expected by **late 2026**, with a launch planned for **early next year** .

### Is Novo in trouble?

**Not in trouble, but under pressure.** Novo built the obesity drug market with Wegovy and Ozempic, but it's losing ground to Eli Lilly. The CagriSema head-to-head loss was a setback. A shareholder lawsuit alleging misleading statements about trial design is ongoing . And Novo plans steep U.S. price cuts for Wegovy, Ozempic, and Rybelsus starting in January 2027—a move that could compress margins .

### What does this mean for patients?

More options. CagriSema is a genuinely effective drug. If approved, it will give patients and doctors another choice—particularly for women, who made up the majority of the trial population and showed strong results in the analysis. Competition between Novo and Lilly is driving innovation and, eventually, lower prices.

### What should investors watch next?

The **FDA decision on CagriSema**, expected in the fourth quarter of 2026. The launch trajectory in early 2027. And Novo's ability to defend its market share against Lilly's Zepbound and forthcoming oral GLP-1 pill. The 25% women analysis is a data point, not a turning point.

---

## The Path Forward: What to Watch

### The FDA Decision

This is the binary event. If CagriSema is approved with a strong label, Novo has a new product to compete with Zepbound. If the label is narrow or comes with restrictions, the uphill battle continues.

### The Launch Trajectory

Novo plans to launch CagriSema in early 2027. Watch the initial prescription numbers. If doctors embrace it as a differentiated option for women or for patients who haven't responded well to GLP-1s alone, Novo has a winner. If it's seen as "just another GLP-1," the launch will disappoint.

### The Price War

Novo is cutting U.S. list prices for Wegovy, Ozempic, and Rybelsus to **$675 per month** starting in January 2027 . That's a bold move to expand access—and a defensive one against Lilly. Watch whether it stabilizes Novo's market share or just compresses margins without stopping the erosion.

### The Shareholder Lawsuit

A federal judge allowed parts of a securities fraud lawsuit to proceed, alleging Novo misled investors about CagriSema's trial design and tolerability . Watch for developments—a settlement or a trial could create headlines and volatility.

---

## Conclusion: The 25% That Comes With an Asterisk

Here's what I want you to take away from Novo's announcement.

CagriSema is a **genuinely effective drug**. A 22.7% average weight loss in a full trial is remarkable. The 25% result in women who stayed on treatment is even more impressive. Novo has built something real, and it will help a lot of people.

But the market doesn't trade on "genuinely effective." It trades on **relative efficacy, competitive positioning, and execution**. And on those measures, Novo is still playing catch-up to Eli Lilly.

The 25% headline is a data point that Novo's PR team will repeat often. The asterisk—that it's an ideal-scenario analysis—is what the FDA and physicians will focus on.

For American investors, the message is simple: **CagriSema is a good drug in a market that demands great ones**. Novo's future depends on whether "good" is enough to hold market share against a competitor that's already proven itself better in a head-to-head fight.

The FDA decision comes soon. The real test comes after.

---

## Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any securities. The author is not a licensed financial advisor. All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Readers should conduct their own research and consult with a qualified financial professional before making any investment decisions. Data and figures cited are accurate as of the date of publication but may change. The author holds no position in any securities mentioned.

---

**Tags:** #NovoNordisk #CagriSema #ObesityDrug #WeightLoss #GLP1 #Wegovy #Ozempic #EliLilly #Zepbound #Mounjaro #PharmaStocks #StockMarketToday #FinancialNews #MarketAnalysis #Investing #NVO #LLY #FDA #DrugApproval #Biotech #HealthcareStocks #ObesityEpidemic #WomenHealth #Menopause #ClinicalTrials #DrugDevelopment #PharmaceuticalIndustry #StockMarket #InvestmentStrategy #HealthcareInvesting